<DOC>
	<DOCNO>NCT03030183</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy RA101495 patient Paroxysmal Nocturnal Hemoglobinuria ( PNH ) inadequate response eculizumab . Patients treat RA101495 12 week .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study RA101495 Treat PNH Patients Who Have Inadequate Response Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Diagnosis PNH flow cytometry Inadequate response eculizumab define receive eculizumab least 6 month plus documented LDH level â‰¥ 1.5 x upper limit normal ( ULN ) and/or presence know C5 mutation confer resistance eculizumab History meningococcal disease Current systemic infection suspicion active bacterial infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>